Overview
OUR PIPELINE
Our CARMA knowledge and experience, coupled with our strong and growing non-clinical and translational research program and established GMP cell processing capabilities forms the basis of our cell therapy R&D platform and underscores the potential for generating a pipeline of highly differentiated, CARMA cell therapies for cancer as well as other diseases with serious unmet needs.
To date, supported by preclinical efficacy, our lead CARMA program, MCY-M11, a mesothelin directed CAR-PBMC therapy, is being evaluated in a Phase I clinical trial for ovarian cancer and peritoneal mesothelioma [NCT03608618]. In addition, we are also advancing research and development of next-generation CARMA-based cell therapies — those potentially engineered with functionality uniquely amenable to the CARMA approach — directed to mesothelin and other novel, undisclosed targets.
CARMA™ IN THE NEWS
CARMA Cell Therapies™ to Share Results of In-vitro Characterization of MCY-M11 at SITC 2020 Annual Meeting
November 9, 2020
Read Full Release
CARMA Cell Therapies™ Expands Phase I Trial of Anti-Mesothelin mRNA CAR-PBMC Cell Therapy MCY-M11
August 18, 2020
Read Full Release
MaxCyte to Share Preliminary Phase I Data on MCY-M11 at ASCO 2020 Annual Meeting
May 18, 2020
Read Full Release
MaxCyte Provides Business Update Related to COVID-19 Pandemic
April 9, 2020
Read Full Release
MaxCyte Appoints New Executive Vice President, Business Development for CARMA™ Cellular Therapies and Provides Clinical Trial Update
December 19, 2019
Read Full Release
MaxCyte to Present at BIO-Europe 2019
November 7, 2019
Read Full Release
MaxCyte Advances Phase I Clinical Trial of Lead CARMA™ mRNA-based Cell Therapy to Third Cohort of Patients
October 24, 2019
Read Full Release
MaxCyte to Provide Updates on First-in-class CARMA™ Platform at BIO Investor Forum
October 15, 2019
Read Full Release
MaxCyte Presents Updates on First-in-class CARMA™ Platform at Upcoming Meetings
September 30, 2019
Read Full Release
MaxCyte Adds Vice President, Non-Clinical and Translational Studies, to Support Advancement of Programs from Its CARMA™ Platform
July 23, 2019
Read Full Release
MaxCyte Progresses Phase I Clinical Trial of Lead mRNA-based Cell Therapy from its CARMA™ Platform
May 8, 2019
Read Full Release
MaxCyte Presents at 22nd Annual ASGCT Meeting on Manufacturing Process for First CARMA™ Drug Candidate, Including One-Day Cell Processing
May 1, 2019
Read Full Release
MaxCyte to Present on CARMA™ Platform at Two Upcoming Industry Conferences in Europe
March 18, 2019
Read Full Release
MaxCyte to Present on Its CARMA™ Platform During Biotech Showcase™and Phacilitate: Leaders World/World Stem Cell Summit 2019
December 19, 2018
Read Full Release
MaxCyte to Present on CARMA™ Platform at BIO-EUROPE®
October 30, 2018
Read Full Release
MaxCyte Commences Dosing in First Clinical Trial in Solid Tumors
October 10, 2018
Read Full Release
MaxCyte, Inc. to Present on CARMA™ Platform at Two Upcoming Industry Conferences
August 29, 2018
Read Full Release
MaxCyte Receives US FDA Investigational New Drug Clearance for First Clinical Program
16 July 2018
Read Full Release
MaxCyte, Inc. to Present at 2018 BIO International Convention
May 29, 2018
Read Full Release
MaxCyte Appoints Dr.Claudio Dansky Ullmann as Chief Medical Officer
April 25, 2018
Read Full Release
MaxCyte, Inc. to Present at BIO Europe and BIOCapital USA Conferences this Month
March 12, 2018
Read Full Release
MaxCyte to Present Pre-Clinical CARMA Data at AACR Meeting
March 2, 2017
Read Full Release
MaxCyte Announces Strategic Immuno-Oncology Collaboration to Advance New Generation of CAR-based Cell Therapies
December 21, 2016
Read Full Release
MaxCyte Appoints Executive Vice President, Business and Strategic Development
November 2, 2016
Read Full Release
MaxCyte and The Johns Hopkins Kimmel Cancer Center Announce Strategic Immuno-Oncology Collaboration to Advance CAR T-cell Therapies
April 21, 2015
Read Full Release
